HRP20220387T1 - Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima - Google Patents

Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima Download PDF

Info

Publication number
HRP20220387T1
HRP20220387T1 HRP20220387TT HRP20220387T HRP20220387T1 HR P20220387 T1 HRP20220387 T1 HR P20220387T1 HR P20220387T T HRP20220387T T HR P20220387TT HR P20220387 T HRP20220387 T HR P20220387T HR P20220387 T1 HRP20220387 T1 HR P20220387T1
Authority
HR
Croatia
Prior art keywords
laa
group
substituted
nitrogen
carbon
Prior art date
Application number
HRP20220387TT
Other languages
English (en)
Croatian (hr)
Inventor
Pamela Brown
Michael Dawson
Mona SIMONOVIC
Steven Boakes
Esther DUPERCHY
Steven James Stanway
Antoinette Wilson
Stephen Frederick Moss
Original Assignee
Spero Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201404301A external-priority patent/GB201404301D0/en
Priority claimed from GB201421019A external-priority patent/GB201421019D0/en
Application filed by Spero Therapeutics, Inc. filed Critical Spero Therapeutics, Inc.
Publication of HRP20220387T1 publication Critical patent/HRP20220387T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62Polymyxins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20220387TT 2014-03-11 2015-03-11 Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima HRP20220387T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201404301A GB201404301D0 (en) 2014-03-11 2014-03-11 Compounds and combinations
GB201421019A GB201421019D0 (en) 2014-11-26 2014-11-26 Compounds
EP15715172.1A EP3116897B1 (en) 2014-03-11 2015-03-11 Polymyxin derivatives and their use in combination therapy together with different antibiotics
PCT/EP2015/055046 WO2015135976A1 (en) 2014-03-11 2015-03-11 Polymyxin derivatives and their use in combination therapy together with different antibiotics

Publications (1)

Publication Number Publication Date
HRP20220387T1 true HRP20220387T1 (hr) 2022-05-27

Family

ID=52823596

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220387TT HRP20220387T1 (hr) 2014-03-11 2015-03-11 Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima

Country Status (21)

Country Link
US (3) US20170073373A1 (https=)
EP (1) EP3116897B1 (https=)
JP (1) JP6785659B2 (https=)
KR (2) KR20230152779A (https=)
CN (1) CN106232617B (https=)
AU (1) AU2015228898B2 (https=)
CA (1) CA2940455C (https=)
CY (1) CY1125175T1 (https=)
DK (1) DK3116897T3 (https=)
ES (1) ES2910072T3 (https=)
HR (1) HRP20220387T1 (https=)
IL (1) IL247243B (https=)
LT (1) LT3116897T (https=)
MX (1) MX359104B (https=)
PL (1) PL3116897T3 (https=)
PT (1) PT3116897T (https=)
RS (1) RS63138B1 (https=)
RU (1) RU2740190C2 (https=)
SI (1) SI3116897T1 (https=)
TW (1) TWI709575B (https=)
WO (1) WO2015135976A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2855916A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
JP2017512818A (ja) 2014-04-01 2017-05-25 モナシュ、ユニバーシティMonash University 抗菌性化合物としてのポリミキシン誘導体
US12146004B2 (en) 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
WO2016100578A2 (en) 2014-12-16 2016-06-23 Micurx Pharmaceuticals, Inc. Antimicrobial polymyxins for treatment of bacterial infections
CN105030744B (zh) * 2015-07-09 2019-04-19 广州英赛特生物技术有限公司 取代苯胍衍生物作为多粘菌素类抗生素增效剂的应用
EP3356387B1 (en) * 2015-09-29 2024-06-26 Monash University Antimicrobial polymyxin derivative compounds
JP6744622B2 (ja) * 2016-06-16 2020-08-19 学校法人上智学院 ピペリジン化合物の製造方法
CN111527100A (zh) * 2017-11-02 2020-08-11 昆士兰大学 肽类抗生素
RS65128B1 (sr) * 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
WO2022098950A1 (en) 2020-11-06 2022-05-12 Spero Therapeutics, Inc. Compounds
JP7621502B2 (ja) 2021-02-02 2025-01-24 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー ビフェニル誘導体化合物を有効成分として含有する抗菌補助剤及びこの用途
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) * 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
CA2747995A1 (en) * 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) * 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
US8415307B1 (en) * 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
CA2855916A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
KR102354902B1 (ko) * 2013-05-22 2022-01-24 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도

Also Published As

Publication number Publication date
EP3116897A1 (en) 2017-01-18
MX2016011682A (es) 2017-04-27
DK3116897T3 (da) 2022-03-28
KR20230152779A (ko) 2023-11-03
LT3116897T (lt) 2022-05-10
RU2016139978A (ru) 2018-04-13
RU2016139978A3 (https=) 2018-10-17
EP3116897B1 (en) 2022-03-02
US20230322858A1 (en) 2023-10-12
PT3116897T (pt) 2022-04-07
CA2940455C (en) 2023-03-21
CY1125175T1 (el) 2024-12-13
TWI709575B (zh) 2020-11-11
ES2910072T3 (es) 2022-05-11
SI3116897T1 (sl) 2022-06-30
JP2017510570A (ja) 2017-04-13
RU2740190C2 (ru) 2021-01-12
TW201617362A (zh) 2016-05-16
AU2015228898B2 (en) 2018-11-15
IL247243A0 (en) 2016-09-29
US20170073373A1 (en) 2017-03-16
WO2015135976A1 (en) 2015-09-17
CN106232617A (zh) 2016-12-14
JP6785659B2 (ja) 2020-11-18
CN106232617B (zh) 2022-06-24
KR20160135739A (ko) 2016-11-28
MX359104B (es) 2018-09-14
PL3116897T3 (pl) 2022-05-30
AU2015228898A1 (en) 2016-10-20
CA2940455A1 (en) 2015-09-17
US20210221848A1 (en) 2021-07-22
RS63138B1 (sr) 2022-05-31
IL247243B (en) 2020-04-30

Similar Documents

Publication Publication Date Title
HRP20220387T1 (hr) Derivati polimiksina i njihova upotreba u kombinacijskoj terapiji zajedno s različitim antibioticima
BR112016022785B8 (pt) composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3-dioxigenase (ido), composição farmacêutica, e, uso de composto inibidor de triptofano-2,3-dioxigenase (tdo) e/ou indoleamina-2,3dioxigenase (ido) ou de um sal farmaceuticamente aceitável do mesmo para fabricação de um medicamento
JP5756290B2 (ja) 大環状化合物および治療方法
PE20140039A1 (es) Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina
AR101261A1 (es) Compuesto de tetrahidropirrolo[1,2:3,4]imidazo[1,2-c]pirimidin-1(6h)-ona y composición farmacéutica que lo comprende
ZA202200828B (en) 6,7-dihydro-5h-pyrido[2,3-c]pyridazine derivatives and related compounds as bcl-xl protein inhibitors and pro-apoptotic agents for treating cancer
JP2017510570A5 (https=)
BR112018067930A8 (pt) Composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
RU2012108874A (ru) Композиции, содержащие расщепляемые ферментами опиоидные пролекарства с модифицированным кетоном и их дополнительные ингибиторы
PE20150132A1 (es) Compuestos d-aminoacidos para enfermedad hepatica
JP2016527186A5 (https=)
CO6540003A2 (es) Inhibidor de bromodominio de benzodiazepina
PE20090876A1 (es) Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
AR120174A1 (es) Inhibidores del factor d del complemento para administración oral
EA201300617A1 (ru) β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ
HRP20210484T1 (hr) Antimikrobna sredstva koja se temelje na imidazolu
JP2021528449A5 (https=)
AR057162A1 (es) Compuestos de benzamida como inhibidores de la enzima histona desacetilasa (hdac)
AR080228A1 (es) Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion
HRP20151419T1 (hr) Derivati 2-okso-1-imidazolidinil imidazotiadiazola
MX2019012759A (es) Derivados de pirrolopirimidina utiles como inhibidores de la replicacion de los virus de la gripe.